BAP1 and mesothelioma: We observe that BAP1-deficient human mesothelioma cell lines (except H28) are hypersensitive to the combined treatment of EZH2 inhibitor GSK126 and mevalonate pathway inhibitor ZA (Figures 4A and S4A–S4J).